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Abstract
Background and Aims: ADAM [A Disintegrin And Metalloproteinase] is a family of peptidase 
proteins which have diverse roles in tissue homeostasis and immunity. Here, we study ADAM-
like DECysin-1 [ADAMDEC1] a unique member of the ADAM family. ADAMDEC1 expression is 
restricted to the macrophage/dendritic cell populations of the gastrointestinal tract and secondary 
lymphoid tissue. The biological function of ADAMDEC1 is unknown but it has been hypothesised 
to play a role in immunity. The identification of reduced ADAMDEC1 expression in Crohn’s disease 
patients has provided evidence of a potential role in bowel inflammation.
Methods: Adamdec1-/- mice were exposed to dextran sodium sulphate or infected orally with 
Citrobacter rodentium or Salmonella typhimurium. The clinical response was monitored.
Results: The loss of Adamdec1 rendered mice more susceptible to the induction of bacterial 
and chemical induced colitis, as evidenced by increased neutrophil infiltration, greater IL-6 and 
IL-1β secretion, more weight loss and increased mortality. In the absence of Adamdec1, greater 
numbers of Citrobacter rodentium were found in the spleen, suggestive of a breakdown in mucosal 
immunity which resulted in bacteraemia.
Conclusion: In summary, ADAMDEC1 protects the bowel from chemical and bacterial insults, 
failure of which may predispose to Crohn’s disease.
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1. Introduction
ADAM proteins are related to matrix metalloproteases and snake 
venom proteins.1 In recent years, ADAMs have become increasingly 
recognised as important in inflammation and tissue repair, and a grow-
ing interest has developed in the potential role of metalloproteases in 
gut homeostasis and bowel inflammation.2 ADAMDEC1, first iden-
tified in 1997, is the sole member of a subsidiary class of the ADAM 
family.1 It has been linked to a number of inflammatory diseases 
including atherosclerosis,3 pulmonary sarcoidosis,4 osteoarthritis,5,6 
Crohn’s disease,7,8 and to gastrointestinal [GI] malignancies–gastric 
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adenocarcinoma9, 10 and colorectal cancer.11, 12 The physiological role 
of ADAMDEC1 remains to be determined.
ADAMDEC1 is a unique member of the ADAM family: it con-
tains pro- and catalytic domains but has a truncated disintegrin 
domain and lacks the typical transmembrane domain and cytoplas-
mic tail.13 It is believed to be a soluble, secreted protein and has 
recently been identified in osteoarthritis synovial fluid5 and in the 
supernatant from un-stimulated ADAMDEC1-transfected HEK293 
cells.14 It is predicted that the disintegrin site is non-functional as 
the ‘disintegrin loop’, reported to be essential for integrin binding,13 
is missing. The other distinguishing feature of ADAMDEC1 is that 
it is the only mammalian ADAM protease in which a histidine [H] 
is replaced by an aspartic acid [D] residue within the zinc-bind-
ing sequence of the metalloprotease domain, HEXXHXXGXXD, 
[H362D]. The metalloprotease site of ADAMDEC1 has been 
shown to be proteolytically active in vitro but the natural ligands 
remain unclear.14 Recently it has been demonstrated that the unique 
nature of the active site in ADAMDEC1 allows it to escape inhibi-
tion by the tissue inhibitors of metalloproteases 1–3 [TIMP1-3].15 
ADAMDEC1 seems to have evolved to function independently 
from the normal intrinsic inhibitory mechanisms that regulate other 
metalloproteases.
The tissue distribution of ADAMDEC1 in the non-inflamed, 
steady state is almost exclusively in the GI tract and to a lesser 
extent in lymphoid tissue and spleen in humans.16 At a cellular 
level, ADAMDEC1 expression has been identified in macrophages 
isolated from non-inflamed human intestine16 and in mature CD40 
activated CD11c+ dendritic cells from the thymus and tonsils.17,18 
Although undetectable in monocytes, in vitro it is upregulated when 
these cells mature to macrophages and more rapidly if this occurs 
in the presence of lipopolysaccharide [LPS] or 1α, 25-dihydroxy 
vitamin D3.
16 This responsiveness to LPS and the association with a 
number of inflammatory diseases have resulted in speculation that 
ADAMDEC1 has an active role in the immune system, but no con-
clusive evidence has been presented to date.
We have used three different bowel inflammation models, dextran 
sodium sulphate [DSS], Citrobacter rodentium [C.  rodentium], and 
Salmonella typhimurium [S.  typhimurium] in Adamdec1-deficient 
mice to determine whether the lack of this molecule alters the suscepti-
bility or immune response to these insults. We have demonstrated that 
in the absence of Adamdec1, mice are more susceptible to infection and 
colitis. These findings suggest a physiological role for ADAMDEC1 in 
protecting the GI tract against infection and inflammation.
2. Materials and Methods
2.1. Adamdec1+/+ and Adamdec1-/- mice
Animal studies were performed in accordance with the UK Animals 
[Scientific Procedures] Act 1986 and European Directive 2010/63/
EU on the protection of animals used for scientific purposes. 
Adamdec1+/- mice were generated by targeted mutagenesis of the 
Adamdec1 gene 1227 on chromosome 8 and insertion of a neomy-
cin-resistant cassette into exon 11. The line was reconstituted from 
frozen embryos from the Deltagen repository. Embryonic stem cells 
were re-derived from 129/OlaHsd mice. The chimeric mice were 
back-crossed onto C57BL/6 mice [Charles Rivers] for a minimum 
of 6 generations. Adamdec1+/+, Adamdec1-/-, and C57BL/6 wild-type 
mice were bred and maintained in specific pathogen-free [SPF] cages 
in the Biological Sciences Unit, UCL. Genotyping was performed 
by polymerase chain reaction [PCR] using Adamdec1 wild-type 
gene-specific primers: AGCTTGAGCGCAAACCCAATGCTTC and 
CCTCAGGTACTGATTCATCACACAG, 322bp, and Adamdec1-/- 
mice primers: GACGAGTTCTTCTGAGGGGATCGATC and 
CCTCAGGTACTGATTCATCACACAG, 600bp.
2.1.1. Dextran sodium sulphate-induced colitis
Mice at 9–12 weeks old were administered drinking water contain-
ing 2% DSS [MW 36 000–50 000] [MP Biomedicals, Cambridge, 
UK] for 7 days as previously described.41 Mice were weighed daily 
and sacrificed between 0 and 21 days for tissue and blood collection.
2.1.2. Bacterial induced colitis
C. rodentium strain ICC169 was kindly provided by Gad Frankel, 
Imperial College London, UK. C.  rodentium was prepared and 
administered as previously described.42 Adamdec1-/- and Adamdec1+/+ 
mice at 9–12 weeks old were orally gavaged 108 or 109 colony-form-
ing units [CFU] of C. rodentium.
Mice were weighed daily. Faeces and tail bleeds were collected 
for C. rodentium culture and serum cytokine analysis. At set time 
points between 0 and 13  days, mice were culled. Blood from tail 
bleed or cardiac puncture, colons, and spleens were collected. Blood, 
disrupted spleens, and dispersed faeces in phosphate buffered saline 
[PBS] were plated on LB agar plates containing 50 µg/ml nalidixic 
acid, to quantify the C. rodentium.
S. enterica serovar Typhimurium [JT11] was kindly provided by 
Dr Elizabeth de Pinna, Public Health England, UK. S. typhimurium 
was cultured overnight, for 16 h, in LB broth, centrifuged at 4 000g, 
washed and resuspended in sterile PBS. Mice at 9-12 weeks old were 
pretreated with metronidazole [0.75g/l diluted in drinking water] for 
5 days, before restarting drinking water for 20 h, followed by a 4-h 
fast, before oral gavage with 108 S. typhimurium. Mice were then 
monitored and weighed for 48 h.
2.2. Murine large bowel lamina propria cell 
isolation
Colonic lamina propria cells were isolated as previously described.42
2.2.1. Flow cytometry
Murine colonic lamina propria cells were incubated with LIVE/
DEAD® stain [Invitrogen L23105], blocked in CD16/CD32 
Fc block [eBioscience 16–0161] before staining with CD45 
PerCP-Cy™5.5 [BD 550994], CD11b V450 [BD 560455], CD11c 
APC [BioLegend  117309], Gr1 PE [BD  553128] [eBioscience 
11–4801], and CD3 PE-CyTM7 [BD 560591] antibodies, then fixed in 
1% formaldehyde. Cells run on a BD LSR Fortessa [BD Biosciences, 
Oxford, UK] were analysed using FlowJo 7.6.4 [Tree Star, Inc].
2.2.2. Quantitative reverse transcription PCR
Intestinal samples [5  mm] were homogenised in RNAlater 
[Qiagen] using the TissueLyser LT [Qiagen]. RNA was har-
vested using the RNeasy® Mini kit [Qiagen]. Total RNA was con-
verted to complementary DNA [cDNA] using the QuantiTect® 
Reverse Transcription Kit [Qiagen]. Quantitative reverse tran-
scription PCR [qRT-PCR] of mouse Adamdec1 was performed 
using the QuantiFast SYBR® Green PCR kit [Qiagen], in dupli-
cate on a Mastercycler® ep realplex [Eppendorf] [Forward primer: 
GTAATTGAGGCTAAAAAAAAGAATAATGTG, reverse primer: 
GCGTGGCCCAACTCATG]. Normalised mean gene expression 
values ± standard deviation [SD] were determined from duplicate 
cycle threshold [Ct] values for each gene and the housekeeping gene 
peptidylprolyl isomerase A  [Ppia]. Relative transcript levels were 
determined by the 2−ΔΔCt method.43]
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2.3. In situ hybridisation
Predesigned in situ probes were purchased from Source Bioscience 
[human ADAMDEC1 No 2402230 and mouse Adamdec1 No 
1511966], cloned into pT7T3D-PacI and expressed in One Shot® 
TOP10 Chemically Competent E. coli [Lifetechnologies, UK]. Probes 
were linearised with NotI / EcoRI and riboprobes generated using 
the Roche DIG RNA Labelling Kit [SP6/T7] [Sigma, UK]. Healthy 
human colonic and small bowel tissue was obtained from surgi-
cal resection margins from patients at University College London 
Hospital, UCLH [NHS National Research Ethics Project Number 
10/H0806/115]. Specimens were immediately fixed in DepC-treated 
4% PFA overnight followed by cryoprotection in DepC treated 20% 
sucrose in PBS overnight at 4ºC. Bowel was harvested from freshly 
culled C57BL/6 mice fixed and cryoprotected as above and tissue 
was rinsed and fixed in OCT; 20-µm sections were cut, mounted, 
and dried in a desiccator. For hybridisation, the riboprobes were 
diluted 1/1000 in hybridisation buffer [50% deionised forma-
mide, 1 x Denhardt’s solution [Invitrogen], 10% dextran sulphate 
[Sigma], 0.1 mg/ml yeast tRNA [Roche], and 1 x ‘salts’ [0.2M NaCl, 
5mM EDTA, 10mM Tris-HCl, 5mM NaH2PO4.2H2O and 5 mM 
Na2HPO]. Sections were incubated at 65ºC overnight in a humidified 
chamber. Slides were washed three times for 5 min in MABT buffer 
[100 mM Maleic Acid, 150 mM NaCl and 0.1% Tween-20, pH 7.5] 
and twice for 30 min at 65 ºC in 1xSSC, 50% formamide, and 0.1% 
Tween-20. Slides were rinsed for two 5-min washes in MABT buffer. 
Sections were blocked in 2% blocking reagent [Roche], 10% heat-
inactivated sheep serum [GenTex] in MABT buffer for 1 h at room 
temperature in a humidified chamber, then incubated with 1:1000 
AP conjugated anti-DIG Fab fragments [Roche 1093274] diluted in 
2% blocking reagent overnight at 4 ºC. Slides were washed three 
times for 10 min in MABT buffer, then twice for 2 min in GB3 buffer 
[100 mM Tris, pH 9.8, 100 mM NaCl and 50 mM MgCl2]. Slides 
were incubated in developing buffer for nitroblue tetrazolium stain-
ing [100 mM Tris pH 9.8, 100 mM NaCl, 50 mM MgCl2, 5% PVA, 
0.11 mM BCIP and 0.12 mM NBT] for 6 h at 37ºC, protected from 
light in a humidified chamber. Dehydrated slides were mounted in a 
xylene-based mountant [DPX].
2.3.1. Anti-mouse ADAMDEC1 antibody
The catalytic domain of murine Adamdec1 was cloned into a GB1-
pBR22b expression construct and the protein was expressed in E 
coli. This GB1-ADAMDEC1 protein, with the solubility enhancer 
GB1 at the N-terminus and a His tag at the C-terminus, was con-
firmed by mass spectrometry [data not shown]. The protein was 
injected into rabbits to produce the anti-serum.
2.4. Histology and immunohistochemistry
Immunohistochemical staining of non-inflamed human intestinal tis-
sue was performed by University College London Hospital [UCLH] 
histopathology department. Sections were preserved in formalin 
for 24 h before paraffin embedding; 5-μm sections underwent auto-
mated dewaxing. Endogenous peroxidase was blocked using 3–4% 
[v/v] hydrogen peroxide. Sections were stained with monoclonal 
anti-ADAMDEC1 antibody, raised in mouse [clone 6C4 Sigma 
WH0027299M1], 1:100 dilution, for 30 min at room temperature fol-
lowing heat-induced epitope retrieval for 20 min using an EDTA-based 
[pH 9.0] epitope retrieval solution. Signal visualisation using the Bond 
Polymer Refine Detection kit [Leica Biosystems, Nussloch GmbH] 
with DAB Enhancer [Leica Biosystems] was performed on the Bond-
III automated staining platform [Leica Biosystems]. Cell nuclei were 
counterstained with haematoxylin.
Mouse colonic tissue was fixed in 10% neutral buffered for-
malin [CellPath] overnight then paraffin-embedded using a Leica 
TP1050 tissue processor; 5-μm sections were cut, dewaxed, and 
endogenous peroxidase was blocked using 3–4% [v/v] hydrogen 
peroxide. Sections were stained, using a Leica ST4040 linear stainer, 
with VFM Harris’ haematoxylin [CellPath], differentiated in 0.2% 
acid alcohol and Eosin Y [VWR], and mounted in Pertex [Leica 
Biosystems] or blocked with 5% goat serum [Sigma G67G7] [diluted 
in distilled water] and stained with an anti-mouse ADAMDEC1 anti-
body, raised in rabbit at dilution of 1:30 for 60 min at room tem-
perature. Goat anti-rabbit poly-HRP-IgG was applied for 60 min at 
room temperature followed by DAB enhancer solution for 10 min. 
Slides were imaged with a Hamamatsu NanoZoomer 2.0-HT C9600 
[Hamamatsu, Hertfordshire, UK].
2.5. Immunoblot
Mouse bowel was homogenised and lysed in Laemmli sample buffer 
containing β-mercaptoethanol [Sigma], protease inhibitors [Roche], 
and phosphatase inhibitors [Sigma]. Samples run on SDS-PAGE gels 
were transferred onto Hybond-P PVDF membranes [Amersham, 
Buckinghamshire, UK]. Membranes blocked in 5% non-fat milk 
were probed with anti-mouse ADAMDEC1 antibody and actin 
[Sigma A5060, overnight at 4ºC, followed by anti-rabbit IgG-HRP 
[Cell Signaling #7074] for 1 h at room temperature.
C.  rodentium protein lysates were blocked with bovine serum 
albumin [Sigma] followed by serum from Adamdec1+/+ and 
Adamdec1-/- mice. Anti-mouse IgG-HRP was applied for 30 min to 
detect anti-C. rodentium IgG.
Bound antibody was detected using ECL Plus [Amersham], 
exposed to Hyperfilm ECL [Amersham].
2.5.1. Intestinal permeability
Mice were administered 600 mg/kg of fluorescein isothiocyanate 
conjugated dextran [FITC-Dextran], MW 4 000 [Sigma Aldrich, 
FD4], dissolved in 200 µl PBS for gavage following a 3 h fast. After 
4 h, serum samples were collected and serially diluted in PBS. The 
concentration of FITC in serum was determined by spectrophoto-
fluorometry with an excitation of 485 nm and an emission wave-
length of 520 nm using as standard serially diluted FITC-dextran. 
Serum from mice not administered FITC-dextran was used to deter-
mine the background.
2.5.2. Cytokine assays 
Mouse serum TNF, IL6, IL1β, IL10, IFNγ, and KC [CXCL1] levels 
were determined using the Mouse Proinflammatory Ultrasensitive 
plate [Meso Scale Discovery, Rockville, MD, USA] and read on a 
SECTOR® Imager 6 000 [Meso Scale Discovery].
2.5.3. Statistical analysis
Data are presented as mean ± standard error of the mean [SEM] using 
GraphPad Prism 4.03 [GraphPad Software, Inc.]. Statistical signifi-
cance was calculated using paired or unpaired two-tailed Student’s 
t test. Mean differences were considered significant when P < 0.05.
3. Results
3.1. Tissue expression of ADAMDEC1 is highly 
conserved across animal species
In the steady state in humans, expression of ADAMDEC1 is 
almost exclusively restricted to the macrophages of the GI tract.16  
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The gene atlas database, BioGPS [http://biogps.org/#goto  =  wel-
come], revealed a conserved expression pattern for Adamdec1 across 
numerous mammalian species including pigs and gorillas [data not 
shown]. A  low level of expression has also been reported in acti-
vated dendritic cells, from secondary lymphoid organs, in humans 
and mice.13,16 Our results were in accordance with those previ-
ous descriptions. Using a panel of mouse tissues, Adamdec1 gene 
expression was shown to be predominantly in the small intestine, 
caecum and large intestine [Figure  1a]. A  similar expression pat-
tern was also seen in humans [Supplementary Figure 1a, available 
as Supplementary data at ECCO-JCC online]. Adamdec1 expres-
sion was significantly higher in the small intestine compared with the 
colon in both mice [Figure 1b] and endoscopic pinch biopsies from 
healthy human volunteers [Supplementary Figure 1b].
Western blots on colonic lysates from wild-type mice identified two 
distinct bands that were absent from Adamdec1-/- mice [Figure 1c]. 
The higher molecular weight band [~ 42 kDa] migrated in an identical 
manner to a recombinant full-length mouse ADAMDEC1-His tagged 
protein. The lower molecular weight band was roughly the same size, 
~ 35 kDa, as previously reported for active ADAMDEC1 protein.13
In situ hybridisation [Figure  1d] and immunohistochemistry 
[Figure 1e] localised the cells expressing or containing ADAMDEC1 
in the large and small bowel to the lamina propria. These findings 
were replicated in human colonic tissue [Supplementary Figure 1c, 
d]. In both mice and humans the ADAMDEC1-positive cells in 
the intestine were mononuclear and consistent with intestinal 
macrophages by microscopy [Figure  1e]. Intestinal epithelial cells 
were not shown to express ADAMDEC1 in either mice [Figure 1d, e] 
or humans [Supplementary Figure 1c, d].
3.2. ADAMDEC1 expression does not require the 
presence of gut microflora
Due to the restricted tissue expression of ADAMDEC1 to regions 
of the bowel with a high concentration of microorganisms, and the 
increased expression observed in monocyte-derived macrophages 
[MDM] after exposure to LPS, it has been proposed that the gut 
microflora may be responsible for stimulating the induction of this 
gene.16 To test this theory, we measured the expression of Adamdec1 
in germfree (GF) mice. mRNA expression levels were equivalent in 
adult germ-free and wild-type animals [Figure 2a, c], indicating that 
it was not dependent on the presence of gut microflora.
Further evidence to support the presence of Adamdec1 in the germ-
free gut was found in two online datasets. An online embryonic mouse 
gene expression atlas resource [http://www.emouseatlas.org/emap/
home.html] demonstrated that Adamdec1 was expressed in the devel-
oping intestine at embryonic E14.5, before bacteria colonise the gut 
[Figure 2d-f]. Extrapolation of Adamdec1 gene expression from tran-
scriptomic profiles of mesenchymal and epithelial cells isolated from 
the small intestine of E18.5 mice confirmed the presence of Adamdec1 
in the prenatal sterile gut. Significantly higher levels of Adamdec1 
were seen in embryonic intestinal mesenchymal cells compared 
with epithelial cells, similar to humans and adult mice [Figure 2g]. 
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Figure 1. Adamdec1 expression is restricted to the gastro-intestinal [GI ] tract. a. Tissue distribution of Adamdec1 in the mouse. b. Quantitative PCR demonstrates 
that Adamdec1 expression is higher in the small bowel [SB] that the large bowel [LB] of wild-type mice [+/+] relative to housekeeping gene PPIA. No Adamdec1 
expression was detectable in Adamdec1-/- mice [-/-]. c. Western blot analysis was used to investigate the presence of ADAMDEC1 protein in mouse colonic tissue; 
as expected Adamdec1-/- colonic tissue was devoid of protein. Actin was used as a loading control and recombinant mouse ADAMDEC1 [control] was run to 
confirm the specificity of the antibody. d. In situ hybridisation was performed on large [LB] and small [SB] bowel tissue from wild-type and Adamdec1-/- mice 
in order to ascertain the location of the mRNA expression. Adamdec1-expressing cells [blue stain] were restricted to the lamina propria region [yellow arrows], 
and the epithelium [red arrows] demonstrated no expression in either the large or the small bowel. There was no specific staining in the tissue obtained from the 
Adamdec1-/- animals. e. Immunohistochemistry revealed that the ADAMDEC1 protein was highly expressed [brown stain] in cells located in the lamina propria 
[yellow arrows] in mouse small bowel. Knockout tissue demonstrated no specific staining.
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These findings provide supportive evidence that the presence of 
Adamdec1 in the gut is not solely dependent on a microbial stimulus.
3.3. Adamdec1-/- mice do not present a spontaneous 
adverse phenotype
Global gene deletion of Adamdec1 on a murine C57BL/6 background 
resulted in the complete loss of expression at both the mRNA and 
protein levels [Figure 1b-e]. Loss of Adamdec1 had no obvious impact 
on the health of mice maintained in specific pathogen-free [SPF] con-
ditions. Adamdec1-/- mice were fertile, born in expected Mendelian 
ratios [M:F 1:1.1, n = 179, P = 0.5] and displayed no abnormal devel-
opmental phenotype or growth impairment [Supplementary Figure 2b, 
available as Supplementary data at ECCO-JCC online]. Histological 
assessment of the GI tract [Supplementary Figure 2a] and FACS analy-
sis of the colonic leukocyte populations [Figure 4d] revealed no gross 
abnormality in Adamdec1-deficient mice. Loss of Adamdec1 had no 
significant effect on intestinal permeability in the naïve, non-inflamed 
state [Supplementary Figure 2c]. Knockout mice were maintained in 
SPF conditions for up to 1 year without the development of sponta-
neous colitis or any other adverse phenotype. A recent publication 
by Vanden Berghe et al. identified passenger mutations in knock-
out mice generated through the use of 129 and C57BL/6J congenic 
mice.19 Their online software program identified two single nucleo-
tide polymorphisms, close to the Adamdec1 gene, affecting the coding 
sequences of Tnfsf10b and Pnma2 genes, which had a > 90% chance 
of being retained in the Adamdec1-/- mice. Neither of these genes are, 
however, expressed in the colon of wild-type mice either in the naïve 
state or during a dextran sodium sulphate [DSS]-induced colitis [data 
not shown]. It is therefore unlikely that these passenger mutations, 
if present, would have any significant bearing on our studies of gut 
inflammation in Adamdec1-/- and wild-type mice.
3.4. Adamdec1 is upregulated in the intestine 
during DSS-induced colitis and loss of expression 
results in an increased systemic response
Adamdec1-/- and wild-type mice were exposed to the colitogenic 
agent DSS [2% in the drinking water] for 7 days. In wild-type mice, 
Adamdec1 was significantly upregulated in the colon during exposure 
to DSS, and on withdrawal of DSS Adamdec1 levels decreased towards 
baseline, mirroring the inflammatory response [Figure 3a]. Following 
DSS challenge, Adamdec1-/- mice demonstrated an earlier and more 
pronounced systemic response than wild-type counterparts, with sig-
nificantly greater weight loss [Figure 3b] and a higher mortality rate 
[Figure 3c]. Mice lacking Adamdec1 expression lost on average 20% 
of their original body weight and 80% died by Day 9 as compared 
with the wild-type mice which lost on average only 10% of their body 
weight and 20% died. These results clearly show that Adamdec1 defi-
ciency renders mice more susceptible to DSS-induced colitis. Mice het-
erozygous for Adamdec1 demonstrated a response between that of the 
homozygous knockout and that of the wild-type mice [Supplementary 
Figure 3a, b, available as Supplementary data at ECCO-JCC online].
Exposure to DSS for 7 days resulted in increased serum levels of IL-6, 
IL-1β, TNF, KC, IFNγ, and IL-10 in wild-type and Adamdec1-/- mice 
compared with naïve animals [Figure 3d]. Serum levels of IL-6 and IL-1β 
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Figure 2. The expression of Adamdec1 is not dependent on the presence of the gut microbiota. a. In situ hybridisation using an anti-sense probe [AS] for 
Adamdec1 was performed on small bowel sections from wild-type GF mice [20 x magnification]. The presence of Adamdec1-specific mRNA was confirmed in 
this tissue [blue] and the distribution was identical to that seen in the conventional C57BL/6 wild-type mice [Figure 1d]. b. In situ hybridisation using the control 
sense-strand probe [Se] for Adamdec1 demonstrates minimal non-specific binding to the small bowel section from the GF mice. c. Equivalent expression of 
Adamdec1 was seen in wild-type and GF tissue using qPCR. Images d-f are taken from [http://www.genepaint.org, Genepaint Set ID: EG337] and represent, d, 
an MRI section image of an E14.5 C57BL/6 embryo sectioned through the midline. e. A corresponding section was used for in situ hybridisation of Adamdec1 
[5 x magnification]. The yellow box denotes the area of positive Adamdec1 expression. f. This region is shown at an increased magnification. The Adamdec1-
expressing tissue corresponds to the foregut [yellow arrow], midgut [red arrow], and hindgut [blue arrow]. g. Adamdec1 is highly expressed in mesenchymal 
compared with epithelial cells in the embryological gut at E18.5, microarray data set [GSE 6383].
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were significantly elevated in Adamdec1-/- mice on Days 10 and 14 above 
those of the wild-type mice. In contrast, the levels of IL-10 were reduced 
in the knockout animals compared with the wild type. The circulatory 
levels of TNF, IFNγ, and KC were similar in both genotypes.
3.5. Loss of Adamdec1 expression results in an 
increased sensitivity to DSS-induced colitis, with an 
elevation in neutrophil recruitment to the colon and 
increased expression of colonic IL-22 and IL-17
The increased sensitivity of mice lacking Adamdec1 to DSS resulted 
in more pronounced phenotypic changes to the colonic tissue 
[Figure 4 a-c]. There was a significant shortening of the colon in 
wild-type and Adamdec1-/- mice 9 days post initiation of DSS, but 
this was more marked in the knockout animals [Figure  4a, b]. 
Histological examination of the colon revealed that the colitis was 
more severe in the knockout mice than the wild type on Days 5 
and 9 [Figure 4c]. Mice that survived the acute DSS-induced coli-
tis demonstrated restoration of normal colonic architecture by Day 
21, irrespective of genotype [Figure 4c]. These results suggest that 
Adamdec1 plays an active part in the initial inflammatory response 
to DSS, but has a negligible role in the resolution phase after 
removal of the insult.
FACS analysis of colonic leukocyte populations was performed 
pre and post DSS exposure in Adamdec1-/- and wild-type mice 
[Figure  4d-f, Supplementary Figure  4, available as Supplementary 
data at ECCO-JCC online]. There was an elevation in neutrophils 
[CD11b+Gr-1+] in the Adamdec1-/- compared with wild-type mice 
after 3 days of DSS exposure [Figure 4d, e], demonstrating that the 
Adamdec1-deficient animals develop an earlier and more aggres-
sive inflammatory response. No significant difference in the number 
of macrophages [CD11b+ Gr-1-] [Figure  4d, f], dendritic [CD11c+ 
CD11b-] [Supplementary Figure 4a, b], or CD3+ T [data not shown] 
cells was observed; individual T cell subsets were not analysed in 
this study.
Colonic expressions of TGF-β, IL-22, and IL-17 were analysed 
following DSS exposure. No difference in TGF-β was observed 
throughout the course of DSS [Supplementary Figure  4c]. 
However, expressions of IL-22 and IL-17 were exaggerated in 
the knockout mice during DSS-induced inflammation. A  rapid 
increase in IL-22 expression was noted in the Adamdec1-/- mice 
compared with wild-type mice, as early as Day 3; both IL-22 and 
IL-17 were significantly raised in knock out mice on Day 15 and 
returned to baseline wild-type levels on resolution of inflamma-
tion by Day 21.
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3.6. Adamdec1-/- mice are more susceptible to 
C. rodentium-induced colitis
To investigate the potential role of Adamdec1 in bacterial-induced 
colitis we used the Gram-negative enteric bacterium, C. rodentium, 
which is capable of inducing a self-limiting colitis in mice.20 Following 
inoculation with ~ 109 organisms, Adamdec1-/- mice demonstrated 
significantly greater weight loss [Figure 5a] and mortality [Figure 5b] 
than the wild type. Wild-type mice exposed to C. rodentium did not 
demonstrate a significant change in body weight over the duration 
of the assay, and no animals succumbed to the infection. By con-
trast, animals lacking Adamdec1 lost approximately 15% of their 
starting weight and 70% died over the 13-day period. Heterozygous 
[Adamdec1+/-] mice responded in a similar way to the wild type 
[data not shown]. The administration of a 10-times lower inocula-
tion dose of C. rodentium [108] induced a significant loss of weight 
in Adamdec1-deficient animals, whereas the wild-type mice contin-
ued to gain weight over the same period [Supplementary Figure 3c]. 
There was no mortality in either the wild-type or knockout animals 
at this lower inoculation dose [Supplementary Figure 3d]. The num-
bers of C. rodentium in the faeces were similar in both genotypes 
[Figure  5c]. These results demonstrate an increased sensitivity to 
C.  rodentium infection in animals lacking Adamdec1 expression, 
despite adequate intraluminal clearance.
3.7. Adamdec1-/- mice are more susceptible to 
colonic inflammation and systemic infection upon 
C. rodentium infection
Following C.  rodentium inoculation, serum levels of IL-6, IL-1β, 
TNF, KC, IFNγ, and IL-10 were measured in Adamdec1-/- and wild-
type mice. The serum levels of both IL-1β and IL-6 were significantly 
higher in Adamdec1-deficient as compared with wild-type mice by 
Day 13 [Figure 5d]. IL-10, TNF, IL12p40, and KC serum levels were 
similar in both genotypes [Figure 5d and data not shown].
C. rodentium infection induces a colitis of the caecum and colon 
in mice. In Adamdec1-/- mice, a significant increase in the total weight 
of the caecum was observed at 13 days post inoculation, suggest-
ing an increased inflammatory infiltration. In comparison, wild-
type mice did not demonstrate a significant change in caecal mass 
[Figure 6a].
Increased sensitivity to C. rodentium in mice lacking Adamdec1 
may result in an increase in systemic infection. In order to test this, 
spleens were isolated, weighed, and screened for the presence of live 
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C.  rodentium. The splenic weight did not alter during C.  roden-
tium infection in wild-type animals, whereas a significant increase 
in splenic mass was observed in Adamdec1-/- mice by Day 13 
[Figure 5b]. The increase in mass coincided with higher numbers of 
live C. rodentium in the spleens of Adamdec1-/-, compared with wild-
type, mice [Figure 5c, d]. These findings are consistent with impaired 
containment of the bacteria locally in the bowel and increased bac-
terial translocation into the circulation in mice lacking Adamdec1.
It has been reported that clearance of C. rodentium from the gut 
is dependent on B cells and IgG secretion.21 Adamdec1-deficient mice 
are however capable of mounting an antibody response to C. roden-
tium infection. Antibodies against C. rodentium protein lysate were 
detectable by Day 13 in the serum from Adamdec1+/+ and Adamdec1-/- 
mice [Supplementary figure  5, available as Supplementary data at 
ECCO-JCC online]. These results demonstrate that Adamdec1 defi-
ciency does not influence the development of a B cell-mediated adap-
tive immune response to C. rodentium infection.
3.8. Adamdec1-/- mice are more susceptible to 
S. typhimurium infection
S.  typhimurium infection in mice results in a transient systemic 
infection and fever, controlled initially through the activation of 
the innate immune system, followed by generation of an adaptive 
response.22 The major site of infection is in the small intestine where 
access to the host occurs through M cells within the epithelium. Pre-
treatment of mice with antibiotic allows colonisation of the intes-
tine and development of colitis. To assess the role of Adamdec1 in 
protecting the mouse from S. typhimurium infection, antibiotic pre-
treated knockout and wild-type mice were orally gavaged with 108 
live organisms and monitored for 48 h [Figure 7]. Adamdec1-/- mice 
lost a greater proportion of their body weight after S. typhimurium 
inoculation compared with the wild type [Figure  7a] and, at 48 h 
post infection, 55% of the knockout compared with only 11% of 
the wild-type mice had succumbed to the infection [Figure 7b]. These 
results suggest that Adamdec1 provides some protection to the host 
during the early phase of S. typhimurium infection.
4. Discussion
ADAMDEC1 is a unique member of the classical ADAM fam-
ily,13 a group of proteins recognised as critical players in immunity 
and tissue remodelling.23 In the steady state, we have shown that 
ADAMDEC1 is abundantly and almost exclusively expressed in the 
GI tract, particularly in the small bowel. A highly conserved tissue 
expression pattern coupled with an increased susceptibility to GI 
infection upon loss of this protein demonstrates that ADAMDEC1 is 
an important component of the GI immune system.
In the intestinal wall we have demonstrated that ADAMDEC1 
is expressed predominantly in mononuclear cells within the lam-
ina propria in mice and humans. ADAMDEC1 has previously been 
isolated from human colonic macrophages; and extrapolation of 
ADAMDEC1 expression profiles, from online datasets of iso-
lated murine colonic lamina propria cells, supports the finding of 
ADAMDEC1 in resident intestinal macrophage populations, in the 
steady state [GSE27859; GSE42101; GDS2982].16,24–26, Classically 
these CD45+CD11b+F480+CD11c+/-Ly6chiCD103-CX3CR1hi intes-
tinal lamina propria cells are reported as functionally phagocytic, 
bactericidal, non-migratory, tolerant, and derived from peripheral 
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blood monocytes.27–29 In addition, peripheral blood monocytes 
cultured under sterile conditions in vitro upregulate ADAMDEC1 
expression as they differentiate into macrophages.8,16 ADAMDEC1 
is not expressed in resident macrophages from extra-intestinal tis-
sues. A  number of studies and online datasets demonstrate that 
ADAMDEC1 is not detectable in mature macrophage popula-
tions resident in the peritoneum, lung, liver, and adipose tissues 
and is only moderately expressed in mature splenic macrophages 
[GSE56711; GDS2982].24,30 However, during inflammation 
ADAMDEC1 has been reported to be upregulated at sites where 
it is not constitutively expressed, such as lung, joints, and major 
blood vessels in pulmonary sarcoidosis,4 osteoarthritis,5 and 
atherosclerotic plaque instability,3 respectively. This association 
with human inflammatory diseases has led to speculation that 
ADAMDEC1 may play a role in the human immune system and 
acute inflammatory response.13,16
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At a cellular level, we and other investigators have demon-
strated a rapid and robust induction of ADAMDEC1 in response 
to bacterial antigens, in particular LPS,16 which would support 
a role for ADAMDEC1 as a bacterial response gene. It has there-
fore been proposed that ADAMDEC1 expression is a conse-
quence of background priming by LPS in the gut lamina propria.13  
Our results do not support this supposition; we have presented evi-
dence that ADAMDEC1 is also expressed in the GI tract of germ-free 
mice and in the un-colonised sterile prenatal embryological bowel. 
In addition, during MDM differentiation a significant elevation in 
ADAMDEC1 expression is observed in the absence of any bacterial 
ligands. These findings suggest that exposure to bacterial antigens 
is not a prerequisite for ADAMDEC1 expression in MDM or gut.
An alternative explanation for the tissue and cellular expres-
sion of ADAMDEC1 may be found in the origin of resident tis-
sue macrophages. Historically, all tissue-resident macrophages were 
believed to be part of a linear mononuclear phagocytic system and 
originate from circulating blood monocytes, similar to inflamma-
tory macrophages.31 There is, however, a growing body of evidence 
that resident macrophages in the mouse are laid down early in 
development, arise from embryonic progenitors32 in the yolk sac 
and or foetal liver, and undergo clonal expansion in situ with little 
or no contribution from circulating monocytes in adult life. The 
intestine is an exception to this rule and it has recently been shown 
that the resident macrophage population within the adult bowel is 
maintained through continual recruitment of circulating monocytes 
which originate from the bone marrow.33 These findings, coupled 
with in vitro data demonstrating that ADAMDEC1 expression is 
induced during peripheral blood monocyte to macrophage differen-
tiation, suggest that these intestinal macrophages may differ from 
extra-intestinal yolk sac- and foetal liver-derived macrophages.16 
It is probable therefore that the reason ADAMDEC1 is selectively 
expressed in the bowel is because it is the predominant tissue in 
which resident macrophages are derived from the peripheral blood 
monocyte pool in the naïve non-inflamed state. The reported 
expression of ADAMDEC1 in extra-intestinal diseased tissue could 
result from induction of ADAMDEC1 in MDM recruited to sites of 
inflammation.
In contrast to extra-intestinal tissues, ADAMDEC1 has been 
identified as significantly under-expressed in a number of diseases 
that affect the gut, such as GI cancers and Crohn’s disease.7–9,11,12 
This phenomenon is unlikely to be secondary to bowel inflamma-
tion per se, as we have clearly shown that Adamdec1 is significantly 
upregulated, at a tissue level, in the bowel of mice following exposure 
to a colitogenic agent and induction of an acute colitis. Furthermore, 
ADAMDEC1 has been reported as under-expressed in MDM and 
terminal ileal [TI] tissue from patients with quiescent as well as 
active Crohn’s disease.7,8 We predicted that loss of ADAMDEC1 may 
increase the host’s susceptibility to bacterial infection and intesti-
nal inflammation resulting in the development of Crohn’s disease. 
This theory was substantiated through the use of a number of GI 
infection and inflammatory models in Adamdec1-deficient mice. 
These studies provided evidence supporting a role for ADAMDEC1 
in the immune response of the gut. In pathogen-free conditions, 
the absence of Adamdec1 expression has no noticeable effect on 
murine gut development, but subjecting Adamdec1-deficient mice to 
colitogenic agents revealed an elevated local and systemic inflam-
matory response, increased bacterial translocation and systemic 
infection, and greater mortality. It is plausible that ADAMDEC1 
may also play an important role in human intestinal immunity 
and protection against the development of infection and chronic 
inflammation. These findings provide the first piece of evidence link-
ing ADAMDEC1 to a regulatory role in bowel immunity.
The exact mechanism by which ADAMDEC1 exerts this pro-
tective effect against colitis is yet to be determined. ADAMDEC1 
evolved from a superfamily of zinc-dependent proteolytic enzymes 
which are well recognised to activate and degrade a variety of sub-
strates including chemokines, cytokines, growth factors, and extra-
cellular matrix proteins.2,23,34 By their substrate interactions it has 
become increasingly evident that these metalloproteases influence 
the function and migration of inflammatory cells, maintain tissue 
homeostasis, aid wound healing, and are pivotal in the regulation 
of the innate and adaptive immune response. The proteolytic targets 
of ADAMDEC1, however, remain elusive. A number of metallopro-
teases have been shown to cleave, activate, and in some cases degrade 
IL-1β.35–37 Adamdec1-/- mice display an exaggerated level of serum 
IL-1β and the downstream cytokine IL-6 during both chemical and 
bacterial induced colitis, which would suggest that Adamdec1 may 
play a role in secretion and/or degradation of IL-1β. Both IL-1β and 
IL-6 are crucial for neutrophil recruitment to sites of infection and 
play a central role in preferentially inducing Th17 differentiation, 
independent of TGF-β.38,39 IL-6 has also been reported to contrib-
ute to innate immune-mediated chronic intestinal inflammation by 
promoting production of IL-22 and IL-17 by innate lymphoid cells 
[ILCs].40 Consistent with this finding, expressions of IL-22 and IL-17 
were significantly increased in Adamdec1-/- mice compared with 
wild-type animals, following exposure to DSS and induction of an 
experimental colitis, and no genotype difference was seen in TGF-β 
levels. Further study is required to ascertain the mechanism by which 
Adamdec1 may target IL-1β and IL-6 and delineate the T cell and 
ILC response in Adamdec1-/- mice.
A recent study has identified three other potential substrates [α2-
macroglobulin, carboxymethylated transferrin, and casein] as well 
as demonstrating the lack of responsiveness to the classical ADAMs 
inhibitors TIMP1-3.14,15 It is unclear if the substrates identified so 
far are the true biological targets of ADAMDEC1, but it is plausible 
that ADAMDEC1 has evolved to escape inhibition by endogenous 
metalloprotease inhibitors. Further work is needed to identify the 
biologically relevant ligands for ADAMDEC1 and identify the mech-
anisms responsible for its expression and regulation within the gut 
and inflamed tissue.
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